

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Upadacitinib for treating active psoriatic arthritis after DMARDs [ID2690]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Other appraisals in the same disease area have included recommendations that healthcare professionals should take into account skin colour/physical, sensory or learning disabilities or communication difficulties when using the PASI/PsARC. E.g. Tofactinib appraisal (TA543) includes recommendations 1.3 and 1.4 on cautioning use of PASI and PsARC.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

A similar statement will be required in any recommendation in this appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

None

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
None

Approved by Associate Director (name): Jasdeep Hayre

Date: 07/10/2020